Previous 10 | Next 10 |
Plasmid CDMO alliance supports first gene therapy platform targeting kidney diseases Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics , a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announc...
HCP-ELISA builds upon Company’s HCP-GAPex℠ service, increasing the efficiency and efficacy of HCP assay development Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the dete...
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22 nd , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February...
Summary Charles River Laboratories has proven itself to be a quality player in its space. Shares of the company don't look all that cheap, but they aren't exactly expensive either. When paired with the consistency of its growth and the robust cash flows of the firm, it becomes a dec...
Charles River Laboratories ( NYSE: CRL ) has acquired Chicago, Illinois-based high-throughput screening solutions provider, SAMDI Tech. The purchase price was $50M in cash for the remaining 80% ownership stake in SAMDI Tech that Charles River ( CRL ) did not already own, subje...
– Proprietary Mass Spectrometry Technology Delivering Innovative High-Throughput Screening Capabilities to Accelerate Drug Discovery Timelines – – Advances Partnership Initiated in 2018 – Charles River Laboratories International, Inc. (NYSE: CRL) anno...
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (N...
CDMO partnership to provide adenoviral vector production enabling initiation of clinical trials Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. , a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics,...
This initial launch includes the CliniPrime Fresh Leukopak, supporting clinical trials and commercialization of advanced therapies Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrime TM suite of Good Manufacturing Practice (GM...
Charles River Laboratories ( NYSE: CRL ) traded ~1% lower pre-market Thursday after Jefferies downgraded the non-clinical contract research organization to Hold from Buy, noting concerns on biotech funding and supply constraints. Despite signs of stability, the biotech funding...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...